Key result
Metabolic reprogramming drives cardiac aging through mitochondrial dysfunction and NAD+ depletion as a modifiable therapeutic target.
Why the study?
Cardiac aging is increasingly recognized as a coordinated process of metabolic reprogramming, motivating a synthesis of evidence linking metabolic, epigenetic, and cellular senescence mechanisms to age-related cardiac vulnerability and emerging translational tools.
This review synthesizes evidence demonstrating that cardiac aging is driven by coordinated metabolic reprogramming—involving substrate utilization shifts, mitochondrial dysfunction, NAD+ depletion, nutrient-sensing imbalance, and cellular senescence—representing a potentially modifiable target for preventing and treating age-related cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Preclinical metabolic and senotherapeutic strategies improve cardiac phenotypes; leaves open clinical translation pending standardized endpoints and sex-specific trials.
Cardiac aging is increasingly recognized as a coordinated process of metabolic reprogramming rather than a passive decline in energy production. This Review synthesizes current evidence linking altered substrate utilization, mitochondrial dysfunction, nicotinamide adenine dinucleotide (NAD⁺) depletion, nutrient-sensing imbalance, metabolism-dependent epigenetic remodeling, and cellular senescence to age-related cardiac vulnerability. Aging myocardium exhibits reduced flexibility in fatty acid and glucose oxidation, context-dependent ketone utilization, defective mitochondrial dynamics and mitophagy, and progressive redox disruption; impaired branched-chain amino acid catabolism is more clearly established in failing hearts than in naturally aged myocardium. These metabolic abnormalities interact with the mechanistic target of rapamycin complex 1 (mTORC1), AMP-activated protein kinase (AMPK), and sirtuin networks, converting transient energetic stress into persistent transcriptional and inflammatory programs. Metabolite-sensitive chromatin modifications and the senescence-associated secretory phenotype further reinforce mitochondrial injury, fibrosis, and paracrine dysfunction across cardiomyocytes, fibroblasts, endothelial cells, and immune cells. We also evaluate emerging translational tools, including epigenetic and metabolomic aging clocks, senescence-associated biomarker panels, NAD⁺ precursors, mTOR modulators, AMPK-activating interventions, senolytics, targeted delivery systems, and cell-based therapies. Although many interventions improve cardiac phenotypes in preclinical models, translation remains limited by insufficient validation in naturally aged human myocardium, cell-type heterogeneity, sex- and disease-stage-dependent responses, and the absence of standardized cardiac aging endpoints. A system-level framework integrating metabolic state, biological age, and residual cardiac resilience may enable more precise prevention and treatment of aging-related cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in Cardiac aging and aging-related cardiovascular disease. Metabolic reprogramming interventions (NAD+ precursors, mTOR modulators, AMPK-activating interventions, senolytics) was evaluated. Cardiac aging is driven by coordinated metabolic reprogramming—involving altered substrate use, mitochondrial dysfunction, NAD+ depletion, and senescence—that represents a modifiable therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: